Abstract
Actionable mutations in the epidermal growth factor receptor (EGFR) gene are prevalent in non-small cell lung cancer (NSCLC). The advent of targeted therapy using tyrosine kinase inhibitors (TKIs) has significantly improved patient outcomes. However, the eventual development of resistance poses a substantial challenge. Molecular profiling is essential for tailoring personalized treatment strategies. Case Description: A 61-year-old female patient with NSCLC harboring the L858R mutation in EGFR was initially treated with osimertinib, achieving a complete response. Nevertheless, at 26 months, the disease progressed with the emergence of the L718Q mutation in EGFR. Osimertinib was discontinued, and a regimen of chemoimmunotherapy combined with erlotinib was initiated. The patient achieved a second complete response and remained progression-free for 14 months. Discussion: The L718Q mutation is rare and confers resistance to osimertinib. However, as demonstrated in this case, the mutation may render the tumor susceptible to alternative treatments. Several case reports suggest modest efficacy with various drug combinations, including other TKIs, chemotherapy, and antiangiogenic agents. This case represents one of the longest progression-free survival periods reported in this context. This underscores the importance of re-evaluating molecular targets upon disease progression in EGFR-mutated non-small cell lung cancer (NSCLC).

This publication has 23 references indexed in Scilit: